In preclinical studies with antibody precursors to simtuzumab, inhibition of LOXL2 expression reduced the number of activated fibroblasts, decreased ECM deposition, inhibited angiogenesis, and prevented tumor cell invasion and metastases. In a phase I study in patients with advanced solid tumors, simtuzumab reduced the size of several tumors in some patients.
We assessed the additive efficacy of simtuzumab in a multicenter, randomized, double-blind, placebo-controlled, phase II study of simtuzumab or placebo in combination with FOLFIRI as a second-line therapy in patients with metastatic KRASmutant adenocarcinoma of the colon or rectum not amenable to complete surgical resection, who previously failed fluoropyrimidine and oxaliplatin therapy (ClinicalTrials.gov #NCT01479465). Eligible patients had metastatic disease; Eastern Cooperative Oncology Group performance status (ECOG PS) 2; adequate bone marrow, hepatic, and renal function; and estimated life expectancy >3 months. Patients were randomized 1:1:1 to receive intravenous FOLFIRI in combination with 700 mg simtuzumab, 200 mg simtuzumab, or placebo every 2 weeks in cycles of 28 days until disease progression or unacceptable toxicity; randomization was stratified by ECOG PS 0 versus >0. From December 2011 to March 2014, 255 patients were enrolled and 249 patients received at least 1 cycle of study drug, with a median number of 6 cycles. Overall, 231 (90.6%) patients discontinued study drug, mainly due to disease progression (185 [72.5%]) and adverse events (12 [4.7%] ). The majority of patients were male (128/249, 51.4%) and white (212/249, 85.1%), with a mean (range) age of 60.5 (22.0-85.0) years and a mean 20.3 months from diagnosis. A sequential stepwise hypothesis and a Hochberg testing procedure were used to compare between the two simtuzumab dosing groups versus placebo for PFS, OS, and ORR. The efficacy analyses failed to demonstrate improvement in clinical endpoints upon the addition of simtuzumab to FOLFIRI chemotherapy (Table 1) . Results from additional sensitivity analyses were consistent with the primary analyses. The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group. Among seven adverse events that led to death, a case of febrile neutropenia was deemed related to treatment with FOLFIRI. [FAS] ) based on investigator assessment. Safety analysis set included patients in the FAS population grouped for analyses with treatment assignments designated according to the actual study drug received. Safety assessments included the incidence of adverse events (AEs), infusion site reactions, and clinically relevant changes in laboratory values and vital signs. AEs were coded according to MedDRA version 17.1 and graded per National Cancer Institute Common Toxicity Criteria (CTCAE version 4.03). Overall response rate (ORR) was assessed by the investigator per RECIST v1.1 as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The difference in PFS and OS from placebo was assessed using Kaplan-Meier methods and the stratified log-rank test, adjusted for the stratification factor ECOG 0 or >0 at randomization. Cochran-Mantel-Haenszel test was used for calculating difference in ORR from placebo. A sequential stepwise hypothesis and a Hochberg testing procedure were used to compare between simtuzumab dosing groups versus placebo for PFS, OS, and ORR, per investigator assessment. A number of sensitivity analyses for PFS, OS, and ORR were also performed to confirm the results of primary analyses. A total of 185 PFS events had to be observed in this study to detect a hazard ratio of 0.6 with approximately 90% power at a two-sided 0.05 significance level based on Hochberg procedure to claim that at least one of the simtuzumab treatment groups improved PFS significantly compared with placebo. The estimated sample size was 255 patients.
Investigator's analysis
Level of activity did not meet planned endpoint. SAEs deemed related to simtuzumab/placebo. As this was a double-blind study, the SAEs considered related to simtuzumab were recorded for both treatment arms. SAEs related to FOLFIRI were not collected. n 5 80, safety analysis set. Colorectal cancer (CRC) accounts for 9.7% of all incident cancers worldwide and is the fourth leading cause of cancer mortality [1] . One of the frequent genetic mutations in CRC is in the KRAS gene in the chromosomal instability pathway [2] . KRAS mutation-positive patients do not respond to antiepidermal growth factor receptor antibody therapy [3] and have poorer survival than patients with the KRAS wild-type gene [4] . The currently available therapies for advanced KRASmutated CRC include chemotherapy alone or in combination with antiangiogenic antibodies such as bevacizumab, aflibercept, or ramucirumab [5] . New therapies are urgently needed for this patient population.
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ADVERSE EVENTS BOTH EXPERIMENTAL ARMS
Activated stroma in the tumor environment is associated with higher numbers of activated fibroblasts, which contribute to the desmoplastic reaction [6, 7] . Tumor-associated activated fibroblasts secrete oncogenic growth factors, produce extracellular matrix (ECM), and promote epithelial cell transformation [7, 8] . Lysyl oxidase-like 2 (LOXL2), an enzyme that remodels the ECM, contributes to the maintenance of the pathologic stromal microenvironment in cancer and fibrotic diseases [9] and promotes tumor angiogenesis [10] and metastatic progression [11] . LOXL2 is expressed in desmoplastic tumors, including CRC, with no expression in the adjacent nonneoplastic areas [8, 12] .
Simtuzumab, a humanized IgG4 monoclonal antibody against LOXL2, inhibits its enzymatic activity [13] . In preclinical studies with antibody precursors to simtuzumab, inhibition of LOXL2 expression reduced numbers of activated fibroblasts, decreased ECM deposition [9] , inhibited angiogenesis [14] , and prevented tumor cell invasion and metastases [15] . Of note, in preclinical models, simtuzumab had better efficacy in KRAS mutant cell lines (Gilead Sciences, Inc., data on file). In a phase I study in patients with advanced solid tumors, single agent simtuzumab reduced the size of several tumors in select patients [16] .
In a multicenter, randomized, double-blind, placebo-controlled phase II study, we evaluated the efficacy of simtuzumab or placebo in combination with FOLFIRI as a second-line therapy in patients with metastatic KRAS-mutant CRC who progressed following oxaliplatin-and fluoropyrimidine-containing first-line therapy (ClinicalTrials.gov #NCT01479465).
The key endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RECIST v1.1, and safety. Enrolled patients had stage IV disease; ECOG PS 2; adequate bone marrow, hepatic, and renal function; and estimated life expectancy >3 months. Patients were randomized 1:1:1 to receive intravenous FOLFIRI in combination with simtuzumab or placebo until disease progression or unacceptable toxicity; randomization was stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) 0 vs >0. Patients were scheduled for 2 visits per cycle and a computed tomography (CT) or magnetic resonance imaging (MRI) scan every 8 weeks.
From December 2011 to March 2014, 255 patients were randomized, 249 patients received at least one 28-day cycle of study drug (full analysis set [FAS] ), and 233 (94%) patients received 2 cycles, with a median number of 6 cycles. The majority of enrolled patients were male (128/249, 51.4%) and white (212/249, 85.1%), with a mean (range) age of 60.5 (22.0-85.0) years ( Table 2 ). The mean (SD) time since first diagnosis of colorectal cancer was 20.3 (20.31) months. In total, 42% of patients had 3 or more target lesions at baseline. The most common target lesion sites included liver (73%), lung (45%), and lymph nodes (16%) ( (Fig. 2) . The adjusted HRs for PFS and OS for the simtuzumab arms compared with placebo were all greater than 1. The ORRs in FOLFIRI/simtuzumab 700 mg, FOL-FIRI/simtuzumab 200 mg, and FOLFIRI/placebo were 11.9%, 5.9%, and 10.0%, respectively. The difference (95% CI) in ORR for patients treated with 700 mg FOLFIRI plus simtuzumab versus patients treated with FOLFIRI plus placebo was 2.0% (28.1, 11.9; p 5 .69) and 24.1% (213.3, 4.6; p 5 .33) for patients treated with 200 mg FOLFIRI plus simtuzumab compared with FOLFIRI plus placebo. Results from sensitivity analyses were consistent with the primary analyses.
The safety profile in the patient groups who received FOL-FIRI combined with simtuzumab was not different from patients who received FOLFIRI with placebo. The most common adverse events (AEs) deemed by the investigator to be related to study treatment were fatigue, diarrhea, nausea and neutropenia. AEs greater than or equal to grade 3 were reported in 59.5% in the FOLFIRI/simtuzumab 700 mg group, 67.1% in the FOLFIRI/simtuzumab 200 mg group, and 61.3% in the FOLFIRI/placebo group. Seven AEs leading to death occurred during this study; one case of febrile neutropenia was deemed related to FOLFIRI treatment. None of the deaths on study were considered related to simtuzumab.
In conclusion, the addition of simtuzumab to FOLFIRI did not improve PFS, OS, or ORR in patients with metastatic KRAS mutant CRC. Abbreviations: CI, confidence interval; FAS, full analysis set (all patients randomized and treated with 1 dose of study drug); HR, hazard ratio (numbers in brackets are 95% CIs); OS, overall survival; SIM, simtuzumab. 
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